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ABSTRACT. In eight patients with advanced 
renal insufficiency (inulin clearance 1.4-9.1 ml/ 
min), concentrations of serum calcium (S[CaJ) 
and phosphorus (S[PJ) were maintained normal 
(S[Ca] > 9.0 mg/100 ml, (S[P] < 3.5 mg/lOO 
ml) for at least 20 consecutive days with phos-
phate binding antacids and oral calcium carbonate. 
The initial serum levels of immunoreactive para-
thyroid hormone (S-PTH) were elevated in three 
(426-9230 pg/ml), normal in four (one after sub-
total parathyroidectomy), and not available in 
one. The initial fractional excretion of filtered 
phosphorus ( Cp ) was high in all and ranged 
CIN 
from 0.45-1.05. Following sustained normo-calce-
mia and normo-phosphatemia, S-PTH was reduced 
below control levels in all patients; being normal 
in six and elevated in two. Cp decreased below CrN 
THE DECREASED fractional tubular 
reabsorption of phosphorus in patients 
with chronic renal disease has been attrib-
uted to concurring secondary hyperparathy-
roidism (1-3). However, the persistence of 
high fractional excretion of phosphorus after 
parathyroidectomy (4-6), even with demon-
strable normal serum level of immunoassay-
able parathyroid hormone (6), supports the 
notion that additional factors other than 
secondary hyperparathyroidism may play 
an important role in the regulation of tu-
bular reabsorption of phosphorus in patients 
with advanced chronic renal insufficiency. 
The fall in the fractional excretion of 
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control levels in all patients; it remained high in 
six (of which five had normal S-PTH) and was 
normal ( Cp = 0.01) in two (of which one had 
CIN 
elevated S-PTH). The observed relationship be-
Cp d'h fi h tween S-PTH and -- coul elt er re ect t e 
C]:\T 
inability of the radioimmunoassay for PTH em-
ployed to measure a circulating molecular species 
of PTH which was present in which case the 
actual levels of S-PTH were higher than those 
measured, and/or it could be indicative of the 
presence of additional important factor(s) (other 
than S-PTH) which inhibit tubular reabsorption 
of phosphorus in advanced chronic renal failure. 
(J Clin Endocrinol Metab 35: 213, 1972) 
phosphorus following calcium infusion has 
been generally interpreted as resulting from 
inhibited secretion of parathyroid hormone 
(7-9). Calcium infusion has been shown to 
induce a fall in circulating parathyroid hor-
mone from a high to a lower or to a normal 
level in patients with advanced renal insuffi-
ciency (1 l~ 13); however, no significant 
change in the fractional excretion of filtered 
phosphorus could be demonstrated following 
the infusion (14). 
Sustained normo-phosphatemia and nor-
mo-calcemia, accomplished with phosphate 
restriction and the administration of large 
doses of vitamin D in 6 patients with chronic 
renal failure, was associated with an increase 
in fractional reabsorption of phosphorus to 
normal levels (3). These findings were inter-
preted by the authors as consistent with 
suppression of parathyroid hyperactivity. 
However, the above assumption was not 
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substantiated by measurements of parathy-
roid hormone levels at the beginning and at 
the end of the study. In addition, the admin-
istration of vitamin D per se could have di-
rectly enhanced the tubular reabsorption of 
phosphorus irrespective of the variations in 
the level of circulating parathyroid hormone 
(15-18) . 
In the present study, normo-phosphatemia 
and normo-calcemia were accomplished with 
the administration of aluminum hydroxide 
gel and calcium carbonate without any sup-
plementary vitamin D. The changes in the 
fractional excretion of filtered phosphorus 
were correlated with the levels of immuno-
assayable parathyroid hormone. 
Materials and Methods 
Eight patients with advanced chronic renal 
disease of diverse etiology were studied (Table 
1). The patients were not receiving diuretics or 
supplementary vitamin D and were not treated 
with dialysis. Patient H.L. showed mild radio-
graphic changes of osteitis fibrosa cystica. Pa-
tient RI had severe osteoporosis documented by 
a bone biopsy with multiple rib fractures and 
had been subjected to subtotal parathyroidec-
tomy four months prior to the study. 
Inulin clearances were measured in all pa-
tients at the beginning and at the termination 
of the study. The clearance studies were con-
ducted in a fasting state between 8 AM and 
11 AM. An oral water load was given prior to the 
study (15 mljkg bwt tap water). A priming dose 
of inulin based on the bwt was injected iv and 
was followed by a sustaining dose. The latter 
was infused with a Sigma-motor pump deliver-
ing 1 ml of normal saline per min with inulin in 
an amount calculated on the basis of the pre-
sumptive glomerular filtration rate. Forty-five 
min were allowed for equilibration before three 
timed urine collections were obtained. Each 
urine collection lasted 30 min and a blood sam-
ple was drawn at its midpoint. The patients re-
mained supine during the clearance study with 
the exception of assuming an upright position 
for voluntary voiding. All serum and urine speci-
mens were assayed for creatinine, inulin, phos-
phorus, and calcium. Inulin (19) and creatinine 
(20) were determined by a Technicon Auto-
Analyzer. Inorganic phosphorus was measured 
utilizing the methodology developed by Amer-
ican Monitor Company (21). Calcium was de-
termined with the Norelco Unicam Atomic Ab-
sorption Spectrophotometer. All samples and 
standards were diluted with lanthanum chloride 
to prevent phosphate and protein interference. 
In addition, serum concentrations of creatinine, 
phosphorus and calcium, and urinary excretion 
of phosphorus and creatinine, were measured 
daily through the study. 
Following the initial clearance determinations, 
the patients were treated with 30 ml aluminum 
hydroxide gel (Amphojel) every hour. As the 
serum concentration of phosphorus approached 
the normal range (serum phosphorus 2.5-3.5 
mg/lOO ml), the dose of Amphojel was reduced 
whereas calcium carbonate was started in an 
initial amount of 2.5-5.0 g every hr. The dose 
of calcium carbonate was adjusted to maintain 
the serum calcium concentration in excess of 9.0 
mg/lOO ml. This level of serum calcium and a 
serum phosphorus concentration below 3.5 mg/ 
100 ml were recorded in each patient for at 
TABLE 1. Clinical data of all patients 
Patient Age Sex 
PR 45 F 
DD 35 M 
RI 45 F 
VF 40 F 
MS 21 F 
HL 35 F 
MU 34 M 
MC 54 M 
C1N 
Diagnosis (ml/min) 
Polyc. K. 1.4 
K-W 4.3 
Chr. PN. 3.4 
Chr. GN. 5.3 
Chr.PN. 5.4 
Chr. GN. 9.1 
K-W 4.9 
Med.C. 4.0 
COr 
(ml/min) 
2.3 
8.0 
6.2 
8.0 
8.2 
12.0 
7.6 
4.5 
Osteitis 
fibrosa 
+ 
Abbreviations: Crx-inulin clearance; Ccr-endogenous creatinine clearance; F-female; M-male; Chr. 
GN.-Chronic glomerulonephritis; Polyc. K.-po\ycystic kidney disease; K-W-diabetic nephropathy; Chr. 
PN-chronic pyelonephritis; Med. C.-medullary cystk kidney disease. 
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least 20 consecutive days before the second 
clearance study was performed. 
Serum levels of parathyroid hormone were 
measured by a radioimmunoassay (Hawker, 
C.D., and R.D. Dtiger, Radioimmunoassay of 
Parathyroid Hormone, in preparation) at the 
beginning of the study and after 3 weeks of sus-
tained normo-ca1cemia and normophosphatem;a. 
In patient PV, only the final level of serum para-
thyroid hormone was available. The radioim-
munoassay procedure for parathyroid hormone 
employed pure bovine parathyroid hormone (22) 
as standard and as labeled hormone. An anti-
serum was prepared by immunizing guinea pigs 
against partially purified bovine parathyroid 
hormone (prepared by gel filtration). Dextran-
coated charcoal was used to separate the anti-
body-bound labeled hormone complex from the 
free-labeled hormone. The validity of the assay 
was established by demonstration that the line 
obtained with multiple dilutions of a hyperpara-
thyroid serum was parallel to the line obtained 
with multiple concentrations of the bovine stan-
dard PTH. All unknown serum samples were 
run at three dilutions (each in duplicate) and 
the results for each unknown serum were com-
pared with the results for standard hyperpara-
thyroid and normal sera which were included in 
each experiment. The results for unknown sera 
were accepted only when the slopes for their 
lines were not significantly different from the 
slopes of the lines for the standard sera. The 
results were expressed as picograms per ml (pg/ 
ml) compared to the bovine parathyroid stan-
dard. Normal subjects (N = 61) had a mean 
parathyroid hormone value of 255 pg/ml and 
SD of 82 pg/ml. Ninety-five percent of the sera 
of all normal subjects were within the range of 
mean -I- 2 SD. Values in excess of mean + 2 SD 
(419 pg/ml) were considered as elevated. The 
antiserum employed in the present study was 
evaluated for its affinity for different immuno-
reactive forms of parathyroid hormone. It has 
been found that the antiserum combines with 
both, the large mol wt (9500) and the small mol 
wt (5500-7500) species of immunoreactive 
parathyroid hormone, however, its affinity for 
the former is 10-fold greater than for the latter. 
I t is therefore possible that because of the rela-
tively low sensitivity for the low molecular wt 
species, the radioimmunoassay could underesti-
mate the concentration of the total immunoreac-
tive parathyroid hormone in the serum. 
Results 
The serum levels of calcium and phos-
phorus, the clearances of inulin and phos-
TABLE 2. Changes in renal handling of phosphorus and in serum levels of parathyroid hormone following 
sustained normo-calcemia and normo-phosphatemia 
Sea Sp CIN Tl' Cp Sl''l'H 
Patient (mg/100 rnI) (mg/100 ml) (ml/min) (l-tg/min) CIN (pg/m!) 
C 7.8 8.0 1.4 -5.6 1.05 
PR N 11.2 2.4 1.2 4.6 0.84 309 
C 8.0 7.1 4.3 24.4 0.92 2168 
DD N 10.5 3.1 5.5 44.3 0.74 511 
C 7.8 7.6 3.4 51.7 0.80 393 
RI N 10.7 2.9 3.3 38.2 0.59 250 
C 7.0 5.9 5.3 125.0 0.60 426 
VF N 10.0 3.0 4.8 83.5 0.42 266 
C 8.5 6.2 5.4 143.9 0.57 293 
MS N 10.2 3.4 5.8 112.4 0.43 234 
e 8.5 5.3 9.1 226.7 0.53 9230 
HL N 10.5 2.4 8.0 190.0 0.01 520 
e 6.0 7.4 7.2 293.0 0.45 279 
ML N 9.0 2.1 5.8 120.6 0.01 262 
e 8.3 8.2 4.9 76.3 0.81 382 
MV N 9.7 2.9 4.6 46.7 0.65 165 
Abbreviations: Sea-serum calcium concentration; Sp-serum phosphorus concentration; eIN-inulin clear-
ance; T p-tubular reabsorption of phosphorus; Cp-phosphorus clearnce; ppDlI~serum concentration of 
parathyroid hormone; C--control, N-after sustained normo-calcemia. 
216 POPOVTZER ET AL. JCE&M·1972 Vol 35 • No 2 
phorus and the serum levels of immunoreac-
tive parathyroid hormone before treatment 
and after 20 or more days of sustained nor-
mo-calcemia and normo-phosphatemia, are 
shown in Table 2. Only two patients showed 
a substantial decrease in the fractional ex-
cretion of phosphorus (HL and ML). This 
decrease probably occurred within less than 
one week after starting the treatment, as 
judged from daily measurements of endog-
enous creatinine and phosphorus clearances 
and using the former as a rough estimate of 
GFR. This early fall in ~p was noticed as 
CR 
serum phosphorus reached low values « 2.5 
mg/lOO ml) before serum calcium increased 
to normal levels. The other six patients 
showed variable decreases, but in all the 
fractional excretion remained above 0.40. In 
Cp 
all six patients the lowest values for C 
en 
were observed during the maximal fall in 
serum phosphorus concentration even in the 
presence of abnormally low serl'm levels of 
calcium. A modest fan in fractional excre-
tion of phosphorus following phosphate de-
privation (without sl'bstantial changes in 
serum calcium concentration) was also re-
ported by Slatopolsky et al. (3). 
The initial serum levels of immunoassay-
able parathyroid hormone were elevated 
above normal in three patients, and were 
within the normal range in the remaining 
four. One of the latter group, patient RI, 
had had subtotal parathyroidectomy before 
the study. No significant correlation could 
be found between the fractional excretion of 
phosphorus and the level of immunoreactive 
hormone at the onset of the study. After sus-
tained normo-calcemia and normo-phospha-
temia, the serum level of immunoreactive 
parathyroid hormone decreased in all pa-
tients. In one patient, PR, the initial value 
was not available; however, the final one 
was within the normal range. In two patients 
with highest initial values, the decrement in 
serum parathyroid hormone was most strik-
ing although the final values were still in the 
abnormally high range. Six patients who had 
normal parathyroid hormone levels at the 
end of the study, all except for one (ML), 
had fractional excretion of phosphorus in 
excess of 0.40. Of the two remaining pa-
tients with elevated parathyroid hormone 
levels, at the end of the study the fractional 
excretion of filtered phosphorus was normal 
(0.01) in one and remained elevated in the 
other. No correlation could be demonstrated 
between the level of the hormone and the 
fractional excretion of phosphorus at the 
end of the study. Likewise, there was no sig-
nificant correlation between the decrements 
in the hormone level and the decreases in 
fractional excretion of phosphorus. 
Discussion 
The present study demonstrated that the 
level of circulating parathyroid hormone as 
determined by our radioimmunoassay was 
not the principal determinant responsible for 
the depressed tubular reabsorption of phos-
phorus in 7 out of 8 patients with advanced 
chronic renal failure. The observed high 
fractional excretion of phosphorus in 5 pa-
tients with normal levels of parathyroid hor-
mone and normal serum phosphorus concen-
trations on the one hand, and the normal 
fractional excretion of phosphorus in a pa-
tient with an elevated hormone level on the 
other at the end of the study leads to the fol-
lowing two possible alternatives. 
1. The radioimmunoassay measured only 
a portion of the total circulating immuno-
reactive parathyroid hormone yielding lower 
values than those that actually were present. 
This possibility does not provide an explana-
tion for the elevated hormone level and nor-
I Cp. . HL ma c- III patlent . 
IN 
The explanation for the finding of normal 
initial control levels of immunoassayable 
parathyroid hormone in 3 patients (MS, 
ML and MV) in the present study is not 
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apparent; however, normal levels were also 
reported previously in similar patients by 
other investigators (11-13). It is possible 
that the "normal" levels represent only a 
portion of the total circulating hormone be-
cause the radioimmunoassay was measuring 
primarily one of the two species of immuno-
reactive parathyroid hormone known to cir-
culate in human plasma (23). 
2. In advanced chronic renal failure fac-
tor (s) other than the level of circulating 
parathyroid hormone also play an important 
role in the diminished tubular reabsorption 
of phosphorus. Intrinsic tubular damage has 
been shown to be responsible for decreased 
tubular reabsorption of phosphorus in experi-
mental unilateral acute renal failure (24). 
Tubular leak of phosphate has not been 
shown to be present in unilateral chronic 
kidney disease in experimental animals (1) 
and in humans ( 3). However, this is not 
necessarily true for all patients with chronic 
renal disease. Dissociation between the vari-
ations in the level of immunoreactive para-
thyroid hormone and the fractional excre-
tion of filtered phosphorus has been reported 
in 6 kidney homograft recipients in which, 
following calcium infusion, suppression of 
parathyroid hormone secretion did not cor-
relate with the changes in tubular reabsorp-
tion of phosphorus (25). In these patients 
with renal homografts residual tubular dam-
age could be responsible for persistent phos-
phaturia. 
The fact that extracellular volume expan-
sion activates mechanisms which depress 
both the tubular reabsorption of sodium and 
phosphorus (26) raises the possibility that 
also in chronic renal failure similar associa-
tion between sodium and phosphorus may 
exist and the same mechanism (s) may be 
responsible for both depressed tubular reab-
sorption of sodium and phosphorus (27) . 
Moreover, recently, Weber et al. (28) have 
demonstrated, with a micropuncture tech-
nique using parathyroidectomized rats, the 
presence of natriuretic and phosphaturic 
factor(s) in the serum of a totally parathy-
roidectomized uremic patient. 
The difference between our results and 
those reported by Slatopolsky et al. (3), 
who found a uniform increase in the frac-
tional tubular reabsorption of phosphorus 
to normal levels in 6 patients that main-
tained normal serum levels of calcium for 
comparable periods of time, is not readily 
explicable. The major difference in the pro-
cedure was the use of vitamin D in the latter 
study which could at least partly be respon-
sible for the augmented tubular reabsorption 
of phosphorus (15-18). Also, the degree of 
hypophosphatemia which was attained in 
the latter study was more striking than in 
our study. 
The observed decrease in the level of im-
munoassayable hormone in all patients is 
consistent with the contention that in most 
patients with chronic renal insufficiency, the 
hyperfunction of the parathyroid gland is 
not autonomous and is responsive to varying 
levels of serum calcium. Similar observa-
tions were made by other workers who dem-
onstrated a decrease in the level of immuno-
reactive parathyroid hormone during cal-
cium infusion (10-13), and with hemodial-
ysis utilizing high calcium or high magne-
sium concentrations in the dialysate (29, 
30). It appears, therefore, that all above-
mentioned procedures may be of certain 
therapeutic benefit in the prevention and the 
treatment of secondary hyperparathyroid-
ism in patients with chronic renal disease. 
However great caution should be exercised 
in interpreting the results of immunoreactive 
parathyroid hormone assays in patients with 
chronic renal failure. The immunological 
heterogeneity of circulating parathyroid hor-
mone (31) warrants careful definition of the 
specificity of the antiserum employed. Fur-
thermore, one has to be aware of the inter-
pretive hazards amounted with the assump-
tion that biological and immunological activ-
ities are identical if it has not, in fact, been 
established experimentally. 
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